James Molloy: Congrats on the good quarter.
Richard Eiswirth: Absolutely. Yes.
Operator: [Operator Instructions]. Our next question comes from Yi Chen with H.C. Wainwright.
Yi Chen: My first question is, going forward, do you think YUTIQ will serve as the main driver for top line growth? Or do you think ILUVIEN could provide pretty solid growth as well?
Richard Eiswirth: Yi, that’s a great question. We are — our goal is to drive top line revenue and utilization of the franchise of the low-dose fluocinolone acetonide asset. I do think there are some aspects about YUTIQ that make it easier to adopt, and if that is the way into certain accounts, we will certainly leverage that. I think we’re going to look at the mix of our promotional activities in 2024 across both brands and indications based on what we see over the next couple of months as we’re planning for 2024. So I certainly think that’s a possibility that we try to leverage YUTIQ and are able to grow it faster than ILUVIEN, but we need to learn a little bit more — get a little more experience in the field first.
Yi Chen: Got it. Got it. And do you think the fact that you now market YUTIQ in the U.S. will have a positive impact on your international sales of ILUVIEN for both indications?
Richard Eiswirth: Probably a little bit too early to tell on that as well, although I’ll tell you, there are some learnings and some strategies about the way EyePoint had been taking YUTIQ to market in the U.S. that we can certainly learn from, right, and try to adopt in Europe as well, and we intend to do that. I think 1 of the big advantages of bringing the products together is there are some things that were working really well with ILUVIEN, some things that are working really well with YUTIQ. And on the flip side, maybe some things that weren’t working so well with both brands, and we can try to create best practices across both, which we will try to do across our global markets.
Yi Chen: Okay. And last question, do you believe that adjusted EBITDA will be positive for the second half of the year?
Richard Eiswirth: Yes, I do. Yes, I do. And I think you’ll continue to see improvements in the EBITDA line, obviously. We, frankly, were very pleased to see positive EBITDA in the second quarter because we had planned a lot of the work around the integration of the 2 products together and bringing them into the same sales force. So we’re pleased to see, what, $900,000 of adjusted EBITDA now. I think you’ll see significant improvements to that in third and fourth quarter.
Russell Skibsted: Plus we only had YUTIQ for half the quarter.
Richard Eiswirth: That’s right. Well, I want to thank everybody for — Go ahead, I’m sorry.
Operator: Sorry, I was just saying this concludes our question-and-answer session, and I’m just turning the call back over to you, Rick.
Richard Eiswirth: Thank you very much. I want to thank everyone for participating in today’s call and your interest and support of Alimera. We do look forward to sharing significant progress on bringing these 2 assets together when we report our third quarter results in November. Thank you very much, and have a great day.
Operator: The conference has now concluded. Thank you for attending today’s presentation. You may all now disconnect.
